Analysis
Braveheart Bio priced an upsized initial public offering at $18.00 per share, above its original $15-$17 range, selling 21.25 million shares to raise $382.5 million -- well above the roughly $300 million the cardiovascular biotech had originally targeted. Shares began trading on the Nasdaq Global Market under the ticker BRVE on August 6, according to Bloomberg.
The company is developing BHB-1893, a therapy for both obstructive and non-obstructive forms of hypertrophic cardiomyopathy, in-licensed from China's Hengrui Pharmaceuticals -- part of a broader pattern this year of US biotechs building pipelines around assets acquired from Chinese drugmakers rather than developing them in-house from scratch. Underwriters were granted a 30-day option to buy up to 3.19 million additional shares at the IPO price.
“Underwriters were granted a 30-day option to buy up to 3.19 million additional shares at the IPO price.”
The upsize is a notable data point for a biotech IPO window that spent much of 2024 and 2025 closed to all but the strongest cardiovascular and oncology stories; Braveheart joins a handful of 2026 biotech listings that have priced above range, a reversal from the down-round IPOs and withdrawn offerings that characterized the sector two years ago. Whether that reopening holds depends heavily on how BHB-1893's trial data reads out, given the company has yet to report pivotal efficacy results in humans.
Braveheart's debut -- the second Pulse has tracked for the company -- is a smaller, quieter counterpoint to the software and AI-infrastructure IPOs dominating 2026 headlines -- a reminder that the public markets are absorbing risk capital across sectors, not just the handful of trillion-dollar tech names getting most of the coverage.
